drugset / Trial / NCT00556894
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-03
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Piclidenoson | Small molecule | 0.1 mg | Oral |
| Subject | Piclidenoson | Small molecule | 1 mg | Oral |